Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
tofersen (QALSODY)qalsody.com · Low evidenceQALSODY (tofersen) is the first FDA-approved treatment for adults with amyotrophic lateral sclerosis (ALS) who have a mutation in the SOD1 gene. It targets a genetic cause of ALS and was approved under accelerated approval based on reduction in neurofilament light chain (NfL) levels in the blood.
Parse Score